16/07/2026
FDA approves Merck's daily cholesterol pill 💊
💊 A major breakthrough in cholesterol treatment has arrived.
The US FDA has approved Merck's once-daily cholesterol pill, Lipfendra (enlicitide)—the first oral PCSK9 inhibitor—giving eligible patients a new alternative to cholesterol-lowering injections.
❤️ For millions living with high LDL ("bad") cholesterol, this could make advanced treatment far more convenient. Instead of regular injections, eligible patients may now have the option of taking a once-daily pill.
🩺 The approval is based on late-stage clinical trials showing the medicine significantly lowers LDL cholesterol in a broad range of patients, including those already taking statins and people with familial hypercholesterolemia.
📈 But that's not the only story. The approval is also a major milestone for Merck as it prepares for the future beyond its blockbuster cancer drug, Keytruda, which begins losing key patent protection from 2028.
❓Who can take this medicine? How does it work? Can it replace injections? What do experts expect next? And why are cardiologists around the world watching its long-term results so closely?
👉 Read the full story on Medical News Pakistan: https://www.medicalnews.pk/16-Jul-2026/fda-approves-merck-s-once-daily-cholesterol-pill-offering-alternative-injections
📲 Follow Medical News Pakistan on WhatsApp for real-time health alerts, medical breakthroughs and expert updates: https://whatsapp.com/channel/0029VbArFeUFCCoaD7rQbU0q